Member Info for Dr_DMS

I'm surprised they have 230 people working there, what the hell are they doing?!!!

Novacyt confirmed it possesses dedicated filovirus qPCR platforms and primer-designed assays explicitly equipped to detect the Bundibugyo strain.

Here we go.....

https://www.msn.com/en-gb/health/other/england-world-cup-base-hit-by-ebola-health-alert-as-deadly-disease-becomes-visible-fast/ar-AA24ipkp?ocid=msedgntp&pc=ASTS&cvid=6a180e97f7094305b23aa1b0fa073fcb&cvpid=17a885321548477291d70b112802bd22&ei=6

21st August

Yes, now fully owned by NCYT, those margins should go up to 60% easily

Yeh plus the Australian market is opening up rapidly, reimbursing, and they now have SCDiagnostics....

Could be a super spreader event

It was probably WBAFC having a top up...

Bcos ive been in 6 yrs and they still say the same crap about commercials, have you tried it for that long?

Listened to half then got bored, same old crap, was anything said?

??

Defo a buy

Hmmmmmm.....

I don't think the PGX covers chemo does it?

IVDR Compliance: With the enforcement of the European Union's In Vitro Diagnostic Regulation (IVDR), manufacturers must provide robust, clinical evidence supporting the safety and validity of their diagnostic kits. Consequently, industry players like Novacyt/Yourgene Health have driven market growth by securing IVDR certification for their specialized DPYD assays.

Key Providers: Major players in this market offer targeted SNP detection (Single Nucleotide Polymorphisms) or sequencing assays. Prominent companies in the space include Yourgene Health (Novacyt), Roche (LightMix kits), Tempus, and LGC Clinical Diagnostics, which also produces mutation controls.

Test Economics: The retail cost of an individual DPYD genetic test generally ranges between \(\$100\) and \(\$300\), yielding an excellent cost-to-value ratio for oncology departments and pathology labs

Lyn Rees said the new DPYD test would be released in May and the IVD version in June...

The DPYD (dihydropyrimidine dehydrogenase) market sits within the broader pharmacogenomics and molecular diagnostics market, which is valued at over \(\$4\) billion globally. Because DPYD tests are typically sold as part of wider genetic or oncology testing panels, specific standalone DPYD market reports are generally grouped into the Predictive Diagnostics Market, which is valued at \(\$139\) billion globally by 2031

The value proposition of the DPYD testing market is driven by clinical economics, patient safety, and evolving health mandates:

Cost Savings: The DPYD test generally costs between \(\$100\) and \(\$300\). It screens patients for gene mutations that cause severe, potentially fatal toxicities when administered chemotherapy drugs like 5-fluorouracil (5-FU) and capecitabine.Avoiding

Massive Liabilities: Treating severe chemotherapy toxicity can exceed \(\$180{,}000\) in hospitalization costs. Studies in the UK estimate that upfront DPYD testing saves the NHS roughly £78{,}000 to £99{,}000 per patient over a lifetime by avoiding toxicity-related treatments.Widespread

Adoption: Health guidelines in the EU, UK, and Australia recommend universal DPYD testing prior to prescribing fluoropyrimidine-based chemotherapy. In the US, major health systems—such as Mass General Brigham—are increasingly adopting it

Maybe this is why the directors bought in at 35-40p end of March and didnt sell at 86p

it really is a **** take to from this from 86p to 60p, they should be struck off by fca....

Its been 2-3 million last couple of days

Unless you are on a cruise ship.....

They will make more from the instruments than any assays....